80 related articles for article (PubMed ID: 12433286)
1. Interleukin-7 (IL-7) in patients receiving intensive chemotherapy for acute myelogenous leukemia: studies of systemic IL-7 Levels and IL-7 responsiveness of circulating T lymphocytes.
Wendelbo Ø; Glenjen N; Bruserud Ø
J Interferon Cytokine Res; 2002 Oct; 22(10):1057-65. PubMed ID: 12433286
[TBL] [Abstract][Full Text] [Related]
2. Cytokine responsiveness of mitogen-activated T cells derived from acute leukemia patients with chemotherapy-induced leukopenia.
Bruserud O; Ulvestad E
J Interferon Cytokine Res; 2000 Nov; 20(11):947-54. PubMed ID: 11096451
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
4. The cellular immune system of patients with acute leukemia and severe chemotherapy-induced leukopenia: characterization of T lymphocyte subsets responsive to IL-16 and IL-17.
Bruserud O; von Volkman HL; Ulvestad E
Acta Haematol; 2000; 104(2-3):80-91. PubMed ID: 11154979
[TBL] [Abstract][Full Text] [Related]
5. T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation.
Bruserud O; Ulvestad E; Berentsen S; Bergheim J; Nesthus I
Scand J Immunol; 1998 Jan; 47(1):54-62. PubMed ID: 9467659
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia.
Wendelbo Ø; Nesthus I; Sjo M; Paulsen K; Ernst P; Bruserud Ø
Cancer Immunol Immunother; 2004 Aug; 53(8):740-7. PubMed ID: 15133630
[TBL] [Abstract][Full Text] [Related]
7. Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells.
Bruserud O
Cancer Immunol Immunother; 1998 Jun; 46(4):221-8. PubMed ID: 9671145
[TBL] [Abstract][Full Text] [Related]
8. Effects of azoles on human acute myelogenous leukemia blasts and T lymphocytes derived from acute leukemia patients with chemotherapy-induced cytopenia.
Bruserud O
Int Immunopharmacol; 2001 Nov; 1(12):2183-95. PubMed ID: 11710547
[TBL] [Abstract][Full Text] [Related]
9. Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects on native functional leukemia blasts.
Bruserud Ø; Huang TS; Glenjen N; Gjertsen BT; Foss B
Haematologica; 2002 Jun; 87(6):584-95. PubMed ID: 12031914
[TBL] [Abstract][Full Text] [Related]
10. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells.
Ersvaer E; Liseth K; Skavland J; Gjertsen BT; Bruserud Ø
BMC Immunol; 2010 Jul; 11():38. PubMed ID: 20618967
[TBL] [Abstract][Full Text] [Related]
11. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
Hsu HC; Chiu CF; Tan TD; Chau WK; Tseng CS; Ho CH
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):305-11. PubMed ID: 8605644
[TBL] [Abstract][Full Text] [Related]
12. Effects of imipenem and cilastatin on human T-lymphocytes derived from acute leukemia patients with chemotherapy-induced leucopenia: studies of T-lymphocyte responses in the presence of acute myelogenous leukemia (AML) blast accessory cells.
Bruserud O
Int J Immunopharmacol; 2000 Jan; 22(1):69-81. PubMed ID: 10684990
[TBL] [Abstract][Full Text] [Related]
13. Functional evaluation of proliferative T cell responses in patients with severe T lymphopenia: characterization of optimal culture conditions and standardized activation signals for a simple whole blood assay.
Wendelbo Ø; Bruserud Ø
J Hematother Stem Cell Res; 2003 Oct; 12(5):525-35. PubMed ID: 14594509
[TBL] [Abstract][Full Text] [Related]
14. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels.
Bruserud O; Ulvestad E
Cancer Immunol Immunother; 2000 Sep; 49(7):377-87. PubMed ID: 10999464
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cortes JE; Kantarjian HM; O'Brien S; Giles F; Keating MJ; Freireich EJ; Estey EH
Cancer; 1999 Apr; 85(7):1506-13. PubMed ID: 10193940
[TBL] [Abstract][Full Text] [Related]
16. Lipoteichoic acid derived from Enterococcus faecalis modulates the functional characteristics of both normal peripheral blood leukocytes and native human acute myelogenous leukemia blasts.
Bruserud Ø; Wendelbo Ø; Paulsen K
Eur J Haematol; 2004 Nov; 73(5):340-50. PubMed ID: 15458513
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia.
Ponchel F; Verburg RJ; Bingham SJ; Brown AK; Moore J; Protheroe A; Short K; Lawson CA; Morgan AW; Quinn M; Buch M; Field SL; Maltby SL; Masurel A; Douglas SH; Straszynski L; Fearon U; Veale DJ; Patel P; McGonagle D; Snowden J; Markham AF; Ma D; van Laar JM; Papadaki HA; Emery P; Isaacs JD
Arthritis Res Ther; 2005; 7(1):R80-92. PubMed ID: 15642146
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia.
Glenjen N; Mosevoll KA; Bruserud Ø
Int J Cancer; 2002 Sep; 101(1):86-94. PubMed ID: 12209593
[TBL] [Abstract][Full Text] [Related]
19. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
[TBL] [Abstract][Full Text] [Related]
20. Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?
Bruserud Ø; Wendelboe Ø
Expert Opin Biol Ther; 2001 Nov; 1(6):1005-16. PubMed ID: 11728232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
